SCHEMBL7812665

SCHEMBL7812665

OCCNc1nc2cc(Cl)c(Cl)cc2n1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.72
HSPA8 P11142 4/20 0.46
HSPA5 P11021 2/20 0.46
SLC28A2 O43868 5/20 0.45
FBP1 P09467 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GMNN O75496 1/20 0.41
MAPT P10636 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
STAT6 P42226 1/20 0.41
HIF1A Q16665 1/20 0.41
SLC29A1 Q99808 2/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7812660 1.00 HDAC6 (0.72) HDAC6HSPA8HSPA5SLC28A2FBP1
SCHEMBL7807811 0.91 HDAC6 (0.72) HDAC6HSPA8HSPA5SLC28A2FBP1
SCHEMBL7807814 0.91 HDAC6 (0.72) HDAC6HSPA8HSPA5SLC28A2FBP1
SCHEMBL7809935 0.89 HDAC6 (0.70) HDAC6HSPA8HSPA5SLC28A2FBP1
SCHEMBL7809936 0.89 HDAC6 (0.70) HDAC6HSPA8HSPA5SLC28A2FBP1
SCHEMBL7801027 0.89 HDAC6 (0.75) HDAC6HSPA8HSPA5SLC28A2SMN1; SMN2
SCHEMBL7801031 0.89 HDAC6 (0.75) HDAC6HSPA8HSPA5SLC28A2SMN1; SMN2
SCHEMBL7869879 0.89 HDAC6 (0.68) HDAC6HSPA8HSPA5SLC28A2FBP1
SCHEMBL7869884 0.89 HDAC6 (0.68) HDAC6HSPA8HSPA5SLC28A2FBP1
SCHEMBL7801019 0.87 HDAC6 (0.72) HDAC6HSPA8HSPA5SLC28A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6307043-B1 FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS GLAXO WELLCOME INC. 2001-10-23 US disclosed
US-20010003744-A1 Therapeutic compounds CHAMBERLAIN STANLEY DAWES (US) 2001-06-14 US disclosed
US-6077832-A FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION GLAXO WELLCOME INC. (US) 2000-06-20 US disclosed
EP-0769017-B1 THERAPEUTIC COMPOUNDS WELLCOME FOUND (GB) 2000-05-24 EP disclosed
US-5998605-A Antiviral benzimidazole nucleoside analogues and method for their preparation GLAXO WELLCOME INC. (US) 1999-12-07 US disclosed
WO-1996001833-A1 THERAPEUTIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1996-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003744-A1 Therapeutic compounds ZC3HAV1, HAVCR2, EIF2AK2 HDAC6 78/4885HSPA8 2469/4885HSPA5 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.